12:00 AM
 | 
Jun 02, 2014
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Astellas sales and marketing update

Astellas launched Xtandi enzalutamide in Japan to treat castration-resistant prostate cancer (CRPC). Japan's National Health Insurance (NHI) price for the drug is ¥3,138.80 ($30.76) for a 40 mg capsule. The recommended dose...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >